Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay K Nooka

Showing results (41-50 of 150) with videos related to

Pageof 15
Sort By:
Expert Review of Hematology|May 14, 2021
Selinexor for the treatment of patients with previously treated multiple myelomaClifton C Mo, Sundar Jagannath, Ajai Chari, et al.
Journal of Oncology Practice|July 14, 2018
Myocarditis With Radiotherapy and Immunotherapy in Multiple MyelomaAndres Chang, Tahseen H Nasti, Mohammad K Khan, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple MyelomaLorenzo Cani, Richa Parikh, Nisha S Joseph, et al.
Cancer|September 6, 2013
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trialsAjay K Nooka, Jonathan L Kaufman, Madhusmita Behera, et al.
Cancer|January 22, 2005
Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trialYehuda Z Patt, Manal M Hassan, Richard D Lozano, et al.
Blood Cancer Journal|February 22, 2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experienceKathryn T Maples, Kevin H Hall, Nisha S Joseph, et al.
Haematologica|May 5, 2022
β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myelomaRemya Nair, Vimal Subramaniam, Benjamin G Barwick, et al.
Future Oncology (London, England)|January 23, 2026
Plain language summary of the management of certain side effects of teclistamab in people with multiple myelomaThomas G Martin, Niels W C J van de Donk, Paula Rodríguez-Otero, et al.
Cancer Biology & Therapy|June 2, 2016
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myelomaKatelyn G Ponder, Shannon M Matulis, Sadae Hitosugi, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2020
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With SelinexorJoseph Mikhael, Kimberly R Noonan, Beth Faiman, et al.
Pageof 15

Showing results (41-50 of 150) with videos related to

Sort By:
Pageof 15
Expert Review of Hematology|May 14, 2021
Selinexor for the treatment of patients with previously treated multiple myelomaClifton C Mo, Sundar Jagannath, Ajai Chari, et al.
Journal of Oncology Practice|July 14, 2018
Myocarditis With Radiotherapy and Immunotherapy in Multiple MyelomaAndres Chang, Tahseen H Nasti, Mohammad K Khan, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple MyelomaLorenzo Cani, Richa Parikh, Nisha S Joseph, et al.
Cancer|September 6, 2013
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trialsAjay K Nooka, Jonathan L Kaufman, Madhusmita Behera, et al.
Cancer|January 22, 2005
Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trialYehuda Z Patt, Manal M Hassan, Richard D Lozano, et al.
Blood Cancer Journal|February 22, 2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experienceKathryn T Maples, Kevin H Hall, Nisha S Joseph, et al.
Haematologica|May 5, 2022
β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myelomaRemya Nair, Vimal Subramaniam, Benjamin G Barwick, et al.
Future Oncology (London, England)|January 23, 2026
Plain language summary of the management of certain side effects of teclistamab in people with multiple myelomaThomas G Martin, Niels W C J van de Donk, Paula Rodríguez-Otero, et al.
Cancer Biology & Therapy|June 2, 2016
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myelomaKatelyn G Ponder, Shannon M Matulis, Sadae Hitosugi, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2020
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With SelinexorJoseph Mikhael, Kimberly R Noonan, Beth Faiman, et al.
Pageof 15